RADX furnishes ASX updates: A$35M placement, A$5M SPP, clinical news

Rhea-AI Filing Summary

Radiopharm Theranostics Limited furnished a Form 6-K to share three Australian Securities Exchange announcements dated October 20, 2025. The exhibits include: “RAD completes A$35 M Placement and launches A$5 M SPP,” “RAD Provides Positive Clinical Updates Across Four Programs,” and “Investor Presentation - Clinical Update and Capital Raising.”

The company attached these items as Exhibits 99.1, 99.2, and 99.3. The submission states the materials are furnished, not filed, and are not incorporated by reference unless specifically noted.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of October 2025

Commission File Number: 001-41621

RADIOPHARM THERANOSTICS LIMITED

(Name of Registrant)

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐       No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

RADIOPHARM THERANOSTICS LIMITED

EXPLANATORY NOTE

Radiopharm Theranostics Limited (the “Company”) published three announcements (the “Public Notice”) to the Australian Securities Exchange on October 20, 2025 titled:

“RAD completes A$35 M Placement and launches A$5 M SPP”

“RAD Provides Positive Clinical Updates Across Four Programs”

“Investor Presentation - Clinical Update and Capital Raising”

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

1

EXHIBITS

Exhibit Number		Description
99.1		RAD completes A$35 M Placement and launches A$5 M SPP
99.2		RAD Provides Positive Clinical Updates Across Four Programs
99.3		Investor Presentation - Clinical Update and Capital Raising

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	RADIOPHARM THERANOSTICS LIMITED
Date: October 20, 2025	By:	/s/ Phillip Hains
		Phillip Hains
		Company Secretary

3

FAQ

What did RADX disclose in its latest Form 6-K?

The company furnished three ASX announcements, including a placement and SPP update, clinical program updates, and an investor presentation.

Which exhibits are included with RADX's 6-K?

Exhibit 99.1: A$35 M Placement and A$5 M SPP; 99.2: Clinical updates across four programs; 99.3: Investor presentation.

When were the ASX announcements referenced by RADX made?

They were published on October 20, 2025.

Are the materials in this 6-K considered filed or furnished?

They are furnished, not filed, and are not incorporated by reference unless expressly stated.

What capital actions are referenced in the exhibits for RADX?

The titles reference a A$35 M Placement and a A$5 M Share Purchase Plan (SPP).

What clinical information is referenced in the 6-K exhibits for RADX?

One exhibit is titled “RAD Provides Positive Clinical Updates Across Four Programs.”